Journalist. Writer. Editor. Storyteller.
In a ground-breaking decision, the Food and Drug Administration approved the first gene therapies to treat people with sickle cell disease – a crippling condition that leaves sufferers in life-altering pain.
On Friday, the administration gave the green light to Casgevy and Lyfgenia for the treatment of sickle cell disease in patients 12 years and older.
Read more here
I am a reporter and digital producer for the Civic section of U.S. News & World Report, where I write about breaking news. I came to U.S. News in 2016 as a researcher and writer for the Rankings and Reviews section and in 2017, joined the news team, where I helped launch America 2020. I have previously worked for LifeZette.com as a reporter and social media specialist and was an editor for several outlets at my alma mater. I am a graduate of the Philip Merrill College of Journalism at the University of Maryland, College Park. You can follow me on Twitter (@arlardieri) and Facebook (/AlexaRLardieri) or connect with me on LinkedIn (/in/alexa-lardieri). View more posts
Alexa Lardieri